BillionToOne Q3 revenue rises 47%, raises 2026 outlook

Overview

• Molecular diagnostics firm's Q3 revenue rose 47% yr/yr on higher test volumes and prices

• Q3 net income and diluted EPS increased sharply from prior year

• Company raised 2026 revenue guidance to $460-470 mln, up 51%-54% yr/yr

Outlook

• BillionToOne raises 2026 revenue guidance to $460 mln-$470 mln from $450 mln-$465 mln

• Company expects to maintain profitability at current levels despite continued investment

Result Drivers

• TEST VOLUME GROWTH - Co said 25% increase in total tests delivered drove higher revenue in Q3

• HIGHER AVERAGE SELLING PRICE - 18% rise in average selling price per test contributed to revenue growth, per co

• ONCOLOGY SEGMENT EXPANSION - Oncology clinical testing revenue nearly doubled, reflecting faster growth in this segment

Company press release: ID:nGNX9fZTvc

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for BillionToOne, Inc. is $125.00, about 13.2% above its November 3 closing price of $110.45

Reuters Recommended Reads

• Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

• Nov 3 - Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected].

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)